Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid - 2In a scientific first, biologists recorded a wild wolf potentially using tools
- 3Disability rights activist and author Alice Wong dies at 51
- 4From Exemplary to Current: Famous Rings Available
- 5Check out the exclusive pitch deck Valerie Health used to raise $30 million from Redpoint Ventures to automate healthcare faxes
- Doggie diversity in size and shape began at least 11,000 years ago
- Figure out How to Keep up with and Clean Your Brilliant Bed for Ideal Execution
- Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
- Figure out how to Amplify Your Open Record Reward
- Baidu robotaxi outage in Wuhan caused by 'system failure', police say
- The 10 Most Famous Works of art Ever
- Travels to Dream Objections in Europe
- Watch South Korean startup Innospace attempt its 1st-ever orbital launch today
- 'Stranger Things' Season 5: What's going on with Will Byers? That shocking Volume 1 plot twist, explained.
